Dy, Grace K.

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,849

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 1,733

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,415

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians

Chemotherapy-related skin toxicityLung Cancer Treatments and Mutations

Cited by 331

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Riess, J. W., Gandara, D. R., Frampton, G. M., Madison, R., Peled, N., Bufill, J. A., Dy, G. K., Ou, S.-H. I., Stephens, P. J., McPherson, J. D., et al. (2018) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 240

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Dy, G. K., Govindan, R., Velcheti, V., Falchook, G. S., Italiano, A., Wolf, J., Sacher, A. G., Takahashi, T., Ramalingam, S. S., Dooms, C., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 163

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., & Adjei, A. A. (2008) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 146

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Fenioux, C., Abbar, B., Boussouar, S., Bretagne, M., Power, J. R., Moslehi, J. J., Gougis, P., Amelin, D., Dechartres, A., Lehmann, L. H., et al. (2023) · Nature Medicine

Cancer Immunotherapy and BiomarkersMyasthenia Gravis and Thymoma

Cited by 83

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Ramalingam, S. S., Thara, E., Awad, M. M., Dowlati, A., Haque, B., Stinchcombe, T. E., Dy, G. K., Spigel, D. R., Lu, S., Iyer Singh, N., et al. (2022) · Cancer

Cancer Immunotherapy and BiomarkersPARP inhibition in cancer therapy

Cited by 75

Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis

Power, J. R., Alexandre, J., Choudhary, A., Ozbay, B., Hayek, S. S., Asnani, A., Tamura, Y., Aras, M., Cautela, J., Thuny, F., et al. (2022) · Archives of Cardiovascular Diseases

Viral Infections and Immunology ResearchCancer Immunotherapy and Biomarkers

Cited by 43

PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis

Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., Price, T., Borghaei, H., Schuler, M., Kato, T., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 30

Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.

Li, B. T., Velcheti, V., Price, T. J., Hong, D. S., Fakih, M., Kim, D.-W., Falchook, G. S., Delord, J.-P., Dy, G. K., Ramalingam, S. S., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 27

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

Skoulidis, F., Li, B. T., Govindan, R., Dy, G. K., Shapiro, G., Bauml, J., Schuler, M. H., Addeo, A., Kato, T., Besse, B., et al. (2021) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 24

Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Dy, G. K., Govindan, R., Velcheti, V., Falchook, G. S., Italiano, A., Wolf, J., Sacher, A. G., Takahashi, T., Ramalingam, S. S., Dooms, C., et al. (2022) · Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 16

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

Ma, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., Goff, L. W., Alberts, S., Bui, L. A., Sanghal, A., et al. (2021) · Cancer Chemotherapy and Pharmacology

Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

Cited by 12